López-Bastida J, Oliva-Moreno J, Linertova R, Serrano-Aguilar P. Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016;17(Suppl 1):1–5.
Article
Google Scholar
Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017;12(1):177.
Article
Google Scholar
Federación Española de Enfermedades Raras (FEDER) and the Creer center. [Survey on socio-sanitary needs of people with rare diseases in Spain. ENSERio study. 2016–2017 data]. Madrid [cited 2022 June 1st]. Available from: https://obser.enfermedades-raras.org/wp-content/uploads/2018/12/FINAL-ENSERio_Estudio-sobre-situacion%20de-Necesidades-Sociosanitarias-Personas-con-Enfermedades-Raras-en-Espana.pdf.
Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019;14(1):58.
Article
Google Scholar
Francis F, Hennig S, Korn B, Reinhardt R, de Jong P, Poustka A, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11(2):130–6.
Article
CAS
Google Scholar
Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010;95(4):1846–50.
Article
CAS
Google Scholar
Carpenter TO, Imel EA, Holm IA, de Beur SMJ, Insogna KL. A clinicians guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8.
Article
Google Scholar
Rodríguez-Rubio E, Gil-Peña H, Chocron S, Madariaga L, de la Cerda-Ojeda F, Fernández-Fernández M, et al. Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population. Orphanet J Rare Dis. 2021;16(1):104.
Article
Google Scholar
Rodríguez-Rubio E, Gil-Peña H, Chocron S, Madariaga L, de la Cerda-Ojeda F, Fernández-Fernández M, et al. Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population. Orphanet J Rare Dis. 2021;16(1):154.
Article
Google Scholar
Fuente R, Gil-Peña H, Claramunt-Taberner D, Hernández O, Fernández-Iglesias A, Alonso-Durán L, et al. X-linked hypophosphatemia and growth. Rev Endocr Metab Disord. 2017;18(1):107–15.
Article
CAS
Google Scholar
Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435–55.
Article
Google Scholar
Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, et al. High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR). J Bone Miner Res. 2019;34(3):490–6.
Article
CAS
Google Scholar
Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A. X-linked hypophosphatemia: Management and treatment prospects. Joint Bone Spine. 2019;86(6):731–8.
Article
CAS
Google Scholar
Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189–99.
Article
Google Scholar
Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, et al. Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int. 2021;108(5):622–33.
Article
CAS
Google Scholar
Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325–33.
Article
CAS
Google Scholar
Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, et al. Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis. 2016;11(1):160.
Article
Google Scholar
Ministry of Health Consumer Affairs and Social Welfare. National Statistics Institute. Spain National Health Survey 2011–2012. Available from: https://www.sanidad.gob.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2011/PresentacionENSE2012.pdf.
Skrinar A, Dvorak-Ewell M, Evins A, Macica C, Linglart A, Imel EA, et al. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321–34.
Article
Google Scholar
Gusi N, Pérez-Sousa MA, Gozalo-Delgado M, Olivares PR. Validity and reliability of the spanish EQ-5D-Y proxy version. An Pediatr (Barc). 2014;81(4):212–9.
Article
CAS
Google Scholar
Theodore-Oklota C, Bonner N, Spencer H, Arbuckle R, Chen CY, Skrinar A. Qualitative research to explore the patient experience of X-linked hypophosphatemia and evaluate the suitability of the BPI-SF and WOMAC® as clinical trial end points. Value Health. 2018;21(8):973–83.
Article
Google Scholar
Noyes J, Edwards RT. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. Value Health. 2011;14(8):1117–29.
Article
CAS
Google Scholar
López-Bastida J, Peña-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):141.
Article
Google Scholar
Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Mak. 2005;25(1):56–70.
Article
Google Scholar
Matza LS, Secnik K, Mannix S, Sallee FR. Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK. Pharmacoeconomics. 2005;23(8):777–90.
Article
Google Scholar
Vandewalle B, Amorim M, Ramos D, Azevedo S, Alves I, Francisco T, et al. Value-based decision-making for orphan drugs with multiple criteria decision analysis: burosumab for the treatment of X-linked hypophosphatemia. Curr Med Res Opin. 2021;37(6):1021–30.
Article
CAS
Google Scholar
Sequeira AR, Mentzakis E, Archangelidi O, Paolucci F. The economic and health impact of rare diseases: a meta-analysis. Health Policy Technol. 2021;10(1):32–44.
Article
Google Scholar
Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J. Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc. 2021;5(8):bvab070.
Article
Google Scholar
Jandhyala R. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC Med Res Methodol. 2021;21(1):86.
Article
Google Scholar
Jandhyala R. Concordance between the schedule for the evaluation of individual quality of life-direct weighting (SEIQoL-DW) and the EuroQoL-5D (EQ-5D) measures of quality of life outcomes in adults with X-linked hypophosphatemia. Orphanet J Rare Dis. 2022;17(1):81.
Article
Google Scholar
Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41(5):865–76.
Article
CAS
Google Scholar
Broseta JJ, López LC, Guillén E, Hernández-Jaras J. Impacto en la calidad de vida y otras variables clínicas del adulto con raquitismo hipofosfatémico ligado al cromosoma X (XLH). Nefrologia. 2018;38:32.
Google Scholar
Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987–98.
Article
CAS
Google Scholar
Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416–27.
Article
CAS
Google Scholar
Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383–93.
Article
CAS
Google Scholar
Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, et al. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271–84.
Article
CAS
Google Scholar
Insogna KL, Rauch F, Kamenicky P, Ito N, Kubota T, Nakamura A, et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res. 2019;34(12):2183–91.
Article
CAS
Google Scholar
Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, et al. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021;7(3):e001714.
Article
Google Scholar
Skrinar A, Theodore-Oklota C, Bonner N, Arbuckle R, Williams A, Nixon A, editors. PRO152 Confirmatory psychometric validation of the Western Ontario McMaster Universities Osteoarthritis Inventory (WOMAC) in adult X-linked hypophosphatemia (XLH). ISPOR Conference; 2019 November 2–6; Copenhagen, Denmark
Skrinar A, Theodore-Oklota C, Bonner N, Arbuckle R, Williams A, Nixon A, editors. PRO154 Confirmatory Psychometric Validation of the Brief Pain Inventory (BPI-SF) in adult X-linked hypophosphatemia (XLH). ISPOR Conference; 2019 November 2–6; Copenhagen, Denmark.
Nixon A, Williams A, Theodore-Oklota C, editors. PRO80 Psychometric Validation of the Brief Fatigue Inventory (BFI) in adult X-linked hypophosphatemia (XLH). ISPOR Conference; 2020 May 18–20; Virtual Meeting.
Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: a description and its applications. European Quality of Life scale. Med Clin. 1999;112(Suppl 1):79–85.
Google Scholar
Hernández G, Garin O, Pardo Y, Vilagut G, Pont A, Suárez M, et al. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018;27(9):2337–48.
Article
Google Scholar
EuroQol Research Foundation. EQ-5D-3L User Guide. Basic information on how to use the EQ-5D-3L instrument. Rotterdam, The Netherlands [cited 2022 June 1st]. Available from: https://euroqol.org/wp-content/uploads/2018/12/EQ-5D-3L-User-Guide_version-6.0.pdf.